Although PD-1 or PD-L1 drugs are widely used in lung cancer and melanoma, research on their impacts on triple-negative breast cancer, a refractory breast tumor, is still very limited, as is research on their safety. This evidence concerns the gene PDCD1 and lung carcinoma.